Showing 4,361 - 4,380 results of 32,444 for search '(( 50 ((we decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( a step decrease ))', query time: 1.01s Refine Results
  1. 4361

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  2. 4362

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  3. 4363
  4. 4364
  5. 4365
  6. 4366
  7. 4367
  8. 4368
  9. 4369
  10. 4370
  11. 4371
  12. 4372
  13. 4373
  14. 4374
  15. 4375
  16. 4376
  17. 4377
  18. 4378
  19. 4379
  20. 4380